PMID- 25258340
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20220330
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 59
DP  - 2014 Dec
TI  - Fast BDNF serum level increase and diurnal BDNF oscillations are associated with 
      therapeutic response after partial sleep deprivation.
PG  - 1-7
LID - S0022-3956(14)00272-6 [pii]
LID - 10.1016/j.jpsychires.2014.09.005 [doi]
AB  - OBJECTIVE: Preclinical and clinical studies support a role for brain-derived 
      neurotrophic factor (BDNF) in the pathophysiology of stress-related mood 
      disorders. Furthermore, BDNF seems to be linked to antidepressant action. 
      Available pharmacological treatments for depression are characterized by 
      significant limitations with low efficacy and a major delay until treatment 
      response. This demonstrates the urgent need for more efficient and fast-acting 
      antidepressants. Besides ketamine, sleep deprivation (SD) as well as partial 
      sleep deprivation (PSD) are effective and fast-acting antidepressant methods. 
      However, the underlying molecular mechanisms of SD are not well understood; 
      especially possible mechanisms explaining the rapid, but transient antidepressant 
      effect of SD are unknown. METHODS: We evaluated serum BDNF from 28 patients 
      suffering from major depressive disorder (MDD), who were naive to SD therapy at 
      seven different time points within a 32 h time window before (day 0) and after 
      PSD (day 1). PSD-response was assessed by 6-Items of the Hamilton Depression 
      Rating Scale (HDRS) before (day 0) and at follow-up after 2 weeks (FU2). RESULTS: 
      PSD induced a very fast increase in BDNF serum levels at day 1 which parallels 
      clinical findings, since levels increased with decreasing depression scores in 
      all participants. Notably, responders showed a significant diurnal BDNF serum 
      variation not only after PSD but already before PSD treatment, while diurnal 
      profile of serum BDNF from non-responders did not vary. CONCLUSIONS: The 
      elasticity in diurnal serum BDNF variation is associated with favourable 
      treatment response to PSD in patients suffering from MDD. Therefore, a normalized 
      BDNF serum profile which oscillates in a circadian fashion seems to precede, 
      rather than follow a favourable treatment outcome in depressed patients. 
      Furthermore the fast increase of BDNF is comparable to effects seen with ketamine 
      infusion.
CI  - Copyright (c) 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Giese, Maria
AU  - Giese M
AD  - Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric Clinics of 
      the University of Basel, Basel, Switzerland; Transfacultary Research Platform, 
      Molecular & Cognitive Neuroscience, University of Basel, Basel, Switzerland.
FAU - Beck, Johannes
AU  - Beck J
AD  - Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the 
      University of Basel, Basel, Switzerland.
FAU - Brand, Serge
AU  - Brand S
AD  - Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the 
      University of Basel, Basel, Switzerland.
FAU - Muheim, Flavio
AU  - Muheim F
AD  - Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the 
      University of Basel, Basel, Switzerland.
FAU - Hemmeter, Ulrich
AU  - Hemmeter U
AD  - Psychiatric Service Center St. Gallen, Wil, Switzerland.
FAU - Hatzinger, Martin
AU  - Hatzinger M
AD  - Psychiatric Services Solothurn, Department of Adult Psychiatry, Solothurn, 
      Switzerland.
FAU - Holsboer-Trachsler, Edith
AU  - Holsboer-Trachsler E
AD  - Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the 
      University of Basel, Basel, Switzerland.
FAU - Eckert, Anne
AU  - Eckert A
AD  - Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric Clinics of 
      the University of Basel, Basel, Switzerland; Transfacultary Research Platform, 
      Molecular & Cognitive Neuroscience, University of Basel, Basel, Switzerland. 
      Electronic address: Anne.Eckert@upkbs.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140916
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 250PJI13LM (Mianserin)
RN  - A051Q2099Q (Mirtazapine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Antidepressive Agents, Tricyclic/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Circadian Rhythm/*physiology
MH  - Depressive Disorder, Major/*blood/*therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Mianserin/analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Mirtazapine
MH  - Psychiatric Status Rating Scales
MH  - *Sleep Deprivation
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - BDNF
OT  - Depression
OT  - Sleep deprivation
OT  - Therapy response
EDAT- 2014/09/27 06:00
MHDA- 2015/07/29 06:00
CRDT- 2014/09/27 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/09/02 00:00 [revised]
PHST- 2014/09/04 00:00 [accepted]
PHST- 2014/09/27 06:00 [entrez]
PHST- 2014/09/27 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - S0022-3956(14)00272-6 [pii]
AID - 10.1016/j.jpsychires.2014.09.005 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2014 Dec;59:1-7. doi: 10.1016/j.jpsychires.2014.09.005. Epub 
      2014 Sep 16.